ASCO Updates Recommendations for Managing Hereditary Breast Cancer
FRIDAY, July 9, 2021 -- One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 9, 2021 Category: Pharmaceuticals Source Type: news

Adding checkpoint inhibition to anti-HER2 breast cancer therapy brings no benefit
(European Society for Medical Oncology) Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary. The phase III trial is the first to report data comparing a neoadjuvant anti-HER2 based regimen with or without the anti-PD-L1 antibody atezolizumab in patients with high-risk, HER2-positive early breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2021 Category: International Medicine & Public Health Source Type: news

Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer
Dr Kathy Miller shares the'biggest news in the breast cancer world'from ASCO, with presented data showing the benefit of olaparib in patients with high-risk,BRCA-mutated HER2-negative disease.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

FDA approves margetuximab for metastatic HER2-positive breast cancer
On December 16, 2020, FDA approved margetuximab-cmkb (MARGENZA, MacroGenics) in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

ACE Inhibitor Prevents LVEF Decline After Breast Cancer Drugs ACE Inhibitor Prevents LVEF Decline After Breast Cancer Drugs
For women with HER2-positive early breast cancer, concurrent therapy with ACE inhibitor lisinopril can help to prevent a decline in left-ventricular ejection fraction (LVEF).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 8, 2021 Category: Cancer & Oncology Tags: Cardiology News Source Type: news

' Smart Bomb' Salvage in HER+ Metastatic CRC'Smart Bomb' Salvage in HER+ Metastatic CRC
The higher the HER2 expression, the more benefit patients get from the antibody-drug conjugate trastuzumab deruxtecan for HER2-positive mCRC in the salvage setting, according to a phase 2 report.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASCO: Adding Olaparib Slows High - Risk Early Breast Cancer
Higher rates of invasive disease - free survival seen in adjuvant setting for HER2 - negative early - stage disease with germline BRCA1 or BRCA2 mutations (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 4, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news

IL-6 Levels Predict Distant Breast Cancer Recurrence IL-6 Levels Predict Distant Breast Cancer Recurrence
Interleukin 6 may be a biomarker for distant recurrence of breast cancer among patients treated for stage II-III HER2-negative disease, investigators have found. The evidence was presented at ASCO 2021.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASCO: Adding Olaparib Slows High-Risk Early Breast Cancer
FRIDAY, June 4, 2021 -- The addition of therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in an adjuvant setting improves invasive disease-free survival in early-stage human epidermal growth factor receptor 2 (HER2)-negative... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2021 Category: Pharmaceuticals Source Type: news

Roche presents data on giredestrant, a next generation selective oestrogen receptor degrader for people with hormone receptor-positive, HER-2 negative breast cancer
Basel, 4 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the presentation of new and updated data on giredestrant (formerly known as GDC-9545), an investigational next generation oral selective oestrogen receptor degrader (SERD), in people with hormone receptor (HR)-positive, HER2-negative breast cancer. Breast cancer is now the most common cancer in the world, with HR-positive being the most common subtype representing 70% of cases.1,2 Data from these studies will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2021.“We’re encour...
Source: Roche Investor Update - June 4, 2021 Category: Pharmaceuticals Source Type: news

ECOG-ACRIN research highlights at ASCO 2021
(ECOG-ACRIN Cancer Research Group) Platinum chemotherapy fails for triple-negative breast cancer, basal-like subtype. The first racially diverse trial to look at severe joint pain from aromatase inhibitors shows more postmenopausal Black and Asian women with early breast cancer developed this common/significant syndrome. Less intense therapy for HPV-associated throat cancer shows outstanding three-year survival and quality of life. Inflammation biomarker links to distant recurrence of HER2-negative early breast cancer. Joseph A. Sparano receives ASCO's 2021 Gianni Bonadonna Breast Cancer Award and Lecture. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2021 Category: Cancer & Oncology Source Type: news

Evolving Strategies in Sequencing for HER2+ MBC Therapy Evolving Strategies in Sequencing for HER2+ MBC Therapy
Therapies targeting HER2+ MBC are evolving rapidly. Several recent FDA approvals offer experts an array of new options and prompt a reevaluation of treatments and sequencing strategies.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news

MD Anderson researchers present new findings in targeted and combination therapies at 2021 ASCO Annual Meeting
(University of Texas M. D. Anderson Cancer Center) Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with melanoma, breast cancer, HER2-positive tumors and ovarian cancer. The results of these studies, which will be presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight new advances in drug therapy research to improve patient outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC t...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Tumor marker may help overcome endocrine treatment-resistant breast cancer
(Sanford Burnham Prebys Medical Discovery Institute) A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy. The research offers a new approach to selecting patients for therapy that targets HER2, a protein that promotes the growth of cancer cells, to help avoid disease relapse or progression of endocrine-sensitive disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news

A path to aggressive breast cancer
(Baylor College of Medicine) Following the progression of breast cancer in an animal model revealed a path that transforms a slow-growing cancer type known as estrogen receptor (ER)+/HER2+ into a fast-growing ER-/HER2+ type that aggressively spreads or metastasizes to other organs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 17, 2021 Category: Cancer & Oncology Source Type: news

BERENICE: Further Evidence of Heart Safety of Dual HER2 Blockade BERENICE: Further Evidence of Heart Safety of Dual HER2 Blockade
Final results were presented at ESMO Breast Cancer 2021 on dual HER2 blockade with pertuzumab and trastuzumab on top of anthracycline-based neoadjuvant chemotherapy for early-stage breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Study finds mechanism leading to herceptin resistance and Rx approach to reverse it
(Louisiana State University Health Sciences Center) Research conducted by an international team of scientists discovered a mechanism that leads to Herceptin resistance, representing a significant clinical obstacle to successfully treating HER2-positive breast cancer. They also identified a new approach to potentially overcome it. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 13, 2021 Category: International Medicine & Public Health Source Type: news

Primary Breast Tumors Often Switch HER2 Status on Relapse Primary Breast Tumors Often Switch HER2 Status on Relapse
A substantial proportion of primary breast tumors switch from HER2-0 to HER2-low expression upon relapse, possibly widening the opportunity to treat patients with novel agents.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 11, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Switch of breast tumors to HER2-low in recurrence may provide greater therapeutic options
(European Society for Medical Oncology) The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 8, 2021 Category: Cancer & Oncology Source Type: news

FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer
The accelerated approval is for first-line use in combination with other agents for locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 6, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 5, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Is HER2-Positive Good or Bad?
Title: Is HER2-Positive Good or Bad?Category: Diseases and ConditionsCreated: 5/5/2021 12:00:00 AMLast Editorial Review: 5/5/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 5, 2021 Category: Cancer & Oncology Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) May 5, 2021-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 5, 2021 Category: Drugs & Pharmacology Source Type: news

Effect of COVID - 19 on Breast Cancer Treatment Examined
More patients with estrogen receptor - positive, HER2 - negative breast cancer treated with neoadjuvant endocrine therapy due to COVID - 19 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 3, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Surgery, Conference News, Source Type: news

Xentuzumab/Exemestane/Everolimus in HR+/HER2- Breast Cancer Xentuzumab/Exemestane/Everolimus in HR+/HER2- Breast Cancer
Did patients with locally advanced or metastatic breast cancer realize improvements in progression-free survival after treatment with this triple combination therapy?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 30, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news

Is HER2 Cancer Aggressive?
Title: Is HER2 Cancer Aggressive?Category: Diseases and ConditionsCreated: 4/26/2021 12:00:00 AMLast Editorial Review: 4/26/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 26, 2021 Category: Cancer & Oncology Source Type: news

What Causes HER2 Positive Breast Cancer
What Causes HER2-Positive Breast Cancer? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 21, 2021 Category: General Medicine Source Type: news

Can HER2-Positive Breast Cancer Be Cured?
Title: Can HER2-Positive Breast Cancer Be Cured?Category: Diseases and ConditionsCreated: 4/9/2021 12:00:00 AMLast Editorial Review: 4/9/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 9, 2021 Category: Cancer & Oncology Source Type: news

'A life-changer': NHS England rolls out five-minute breast cancer treatment
New ‘quicker and kinder’ treatment combining drugs cuts length of time some patients have to spend in hospitalA new breast cancer treatment will cut the amount of time some patients have to spend in hospital from two and a half hours to five minutes.The treatment, called Phesgo, is being rolled out across England by the NHS and will be offered to breast cancer patients undergoing chemotherapy. It will be available to people with HER2-positive breast cancer, which accounts for 15% of all such cancers.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 5, 2021 Category: Science Authors: PA Media Tags: Breast cancer NHS Health Society Source Type: news

Is Chemo Necessary for HER2 Positive?
Title: Is Chemo Necessary for HER2 Positive?Category: Diseases and ConditionsCreated: 4/1/2021 12:00:00 AMLast Editorial Review: 4/1/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 1, 2021 Category: Cancer & Oncology Source Type: news

Prognostic value of molecular classification in metastatic breast cancer confirmed
(University of Barcelona) In a study published in the Journal of Clinical Oncology, researchers from the Hospital Cl í nic-IDIBAPS, University of Barcelona and SOLTI showed the predictive capacity of the 4 molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched and Basal-like). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 29, 2021 Category: Cancer & Oncology Source Type: news

T cell circuits that sense antigen density with an ultrasensitive threshold
Overexpressed tumor-associated antigens [for example, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)] are attractive targets for therapeutic T cells, but toxic "off-tumor" cross-reaction with normal tissues that express low levels of target antigen can occur with chimeric antigen receptor (CAR)–T cells. Inspired by natural ultrasensitive response circuits, we engineered a two-step positive-feedback circuit that allows human cytotoxic T cells to discriminate targets on the basis of a sigmoidal antigen-density threshold. In this circuit, a low-affinity synthetic No...
Source: ScienceNOW - March 11, 2021 Category: Science Authors: Hernandez-Lopez, R. A., Yu, W., Cabral, K. A., Creasey, O. A., Lopez Pazmino, M. d. P., Tonai, Y., De Guzman, A., Mäkelä, A., Saksela, K., Gartner, Z. J., Lim, W. A. Tags: Molecular Biology reports Source Type: news

Weight Loss Tied to Worse Breast Cancer Outcomes
MONDAY, March 8, 2021 -- Weight loss during treatment and over two years of follow-up negatively impacts clinical outcomes among women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2021 Category: Pharmaceuticals Source Type: news

FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

The unveiling of a novel mechanism of resistance to immunotherapy targeting HER2
(Vall d'Hebron Institute of Oncology) VHIO investigators report how HER2 breast cancer cells adopt a strategy to resist clearance by redirected lymphocytes. Findings evidence that the disruption of interferon-gamma signaling confers resistance to these immunotherapies and promotes disease progression. Reported in Nature Communications, these results could help to potentiate future immune-based strategies and more precisely identify those patients who would be most likely to benefit from them. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2021 Category: Cancer & Oncology Source Type: news

Unexpected findings on weight loss and breast cancer from international study in JNCCN
(National Comprehensive Cancer Network) New research in the February 2021 issue of JNCCN--Journal of the National Comprehensive Cancer Network examined body mass index (BMI) data for people with HER2-positive early breast cancer, and found a 5% weight loss in patients over two years in was associated with worse outcomes. Weight gain over the same time period did not affect survival rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news

Molecular imaging determines effectiveness of novel metastatic breast cancer treatment
(Society of Nuclear Medicine and Molecular Imaging) Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called 18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news

George Mason, Rutgers partner to better inform HER2 breast cancer treatment
(George Mason University) A George Mason University and Rutgers Cancer Institute of New Jersey collaboration received the U.S. Army's Breast Cancer Research Program (BCRP) Breakthrough Award and $1.33 million in funding to quickly confirm if an identified HER2 biomarker can indicate success likelihood of personalized breast cancer treatments. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 12, 2021 Category: Cancer & Oncology Source Type: news

FDA D.I.S.C.O. Burst Edition: FDA Approvals of Xalkori for patients 1-21 years with ALK-positive ALCL and Enhertu for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Liotta & Petricoin receive funding for breast cancer research
(George Mason University) Lance Liotta, Co-Director, Applied Proteomics and Molecular Medicine, and Emanuel Petricoin, III, Co-Director, Applied Proteomics and Molecular Medicine, received $1,339,358 from the U.S. Department of the Army for a study of HER2+ breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2021 Category: Cancer & Oncology Source Type: news

Novel therapy-resistance mechanism promoting the growth of breast cancer brain metastasis
(University of Turku) SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska's research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. Removing SORLA from cancer cells sensitized anti-HER2 resistant breast cancer brain metastasis to targeted therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2021 Category: Cancer & Oncology Source Type: news

New biosensors quickly detect coronavirus proteins and antibodies
(University of Washington Health Sciences/UW Medicine) Researchers have designed protein-based biosensors that glow when mixed with targeted molecules, such as components of the pandemic coronavirus or specific COVID-19 antibodies. This development could allow for faster, more widespread testing in the near future. Similar biosensors could be designed to detect medically relevant human proteins such as Her2 (a biomarker for some breast cancers) and Bcl-2 (which has clinical significance in some other cancers), as well as a bacterial toxin and antibodies that target Hepatitis B virus. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 28, 2021 Category: Cancer & Oncology Source Type: news

Enhertu Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer
TOKYO& MUNICH& BASKING RIDGE, N.J.--(BUSINESS WIRE) January 15, 2021 -- Daiichi Sankyo Company, Ltd.  (hereafter, Daiichi Sankyo) and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 15, 2021 Category: Drugs & Pharmacology Source Type: news

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 15, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Entinostat Doesn't Overcome Endocrine Resistance in Breast Cancer Entinostat Doesn't Overcome Endocrine Resistance in Breast Cancer
The histone deacetylase inhibitor entinostat failed to overcome resistance to endocrine therapy in hormone receptor –positive, HER2-negative, advanced breast cancer in a phase 3 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient. The image analysis algorithms use artificial intelligence to support pathologists in making faster, more accurate patient diagnoses in breast cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - January 11, 2021 Category: Pharmaceuticals Source Type: news